Pharmalot… Pharmalittle… The Weekend Nears
1 CommentBy Ed Silverman // February 19th, 2010 // 7:57 am
And so once again, another week will soon draw to a close. We hope this has been a productive stretch, although today is not yet history. Still, this may be a good time to ponder the weekend activities. Any interesting plans? We plan to huddle with some of our favorite humans and, of course, walk the dog. While you consider your own possibilities, here are a few items to help you close out the week. Have a nice time, everyone…
Merck To Consolidate Media Spending (AdWeek)
FDA Issues Warnings On Long-Acting Beta Agonists (Bloomberg News)
Novartis’ Tasigna Gets FDA Priority Review (Reuters)
Roche Wins Approval To Market Rituxan For CLL (Bloomberg News)
Novavax Presents Swine Flu Data (Associated Press)
AIDS Vaccine Effect May Wear Off (Reuters)
A patient who knows better
Apparently the FDA has forgotten about the law suit on the illegalities of Tasigna, Well what’s a few Leukemia cancer patients lives worth anyway. If they have instant cardiac death, then it cost the system less.
http://www.pharmalot.com/2007/07/cancerous-data-novartis-stats-whiz-blows-whistle/